Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people’s lives better by making high quality medicines more accessible around the world.
The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.
The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.
Location: United States, New Jersey, Montville Township
Employees: 1001-5000
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | CVC Capita... | cvc.com |
Mentions in press and media 8
| Date | Title | Description |
| 10.06.2024 | NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter | The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression and sui... |
| 28.05.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Ant... | Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" NRX-101 demonstrated a sim... |
| 14.05.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update | 2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor for an initial $7.5 million note, sub... |
| 06.05.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression | Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified anal... |
| 18.04.2024 | NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement | The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicidal Bipolar Depression and Chronic Pain, N... |
| 01.04.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per... |
| 26.09.2017 | Term Sheet — Tuesday, September 26 | FRESH FUNDING Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop Before Sequoia partner Pat Grady committed to the investment, he asked Cancel about whether he was planning to exit ... |
| 22.06.2015 | CVC, Temasek team up to buy $2b generic drugs firm Alvogen | Premium A consortium of investors led by private equity firm CVC Capital Partners, that includes Singapore state fund Temasek, as well as Vatera Healthcare Partners have bought a controlling stake in pharmaceutical company Alvogen. Continue... |